 |
 |
 |
 |
 |
 |
CARDIAC PET: A CASE-BASED APPROACH TO PHARMACOLOGIC STRESS MPI |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| These programs are presented free of charge. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CME INFORMATION Statement of Needs Although cardiovascular disease (CVD) has been and continues to be the scourge of the industrialized world in the 20th and 21st centuries, advancements in noninvasive radiologic diagnostic techniques have led to improved detection and management of this condition. The American Heart Association’s 2006 statistical update reported that since 1900, CVD has been the number one killer in the United States except for the year 1918. CVD claims more lives each year than the next 4 leading causes of death combined, which are cancer, chronic lower respiratory diseases, accidents, and diabetes mellitus. For the subpopulation of CVD patients with coronary artery disease, rapid and accurate diagnosis can facilitate timely clinical decisions that can determine a patient’s treatment, from conservative medical management to coronary artery bypass grafting procedure. The expanded use of noninvasive myocardial perfusion imaging (MPI) has resulted in reduced morbidity and health care costs. Cardiac positron emission tomography (PET)-MPI provides a radiologic technique that complements and even improves upon single photon emission computed tomography (SPECT) imaging. Through the development of advanced cameras and readily available tracers such as rubidium-82, expanded use of cardiac PET, with its benefits, limitations, and unique attributes are documented in peer-reviewed literature. Due to the relatively new application of PET to cardiac disease, health professionals can benefit from education to ensure that the study protocol is performed correctly in order to optimize image quality and minimize artifacts. Additionally, an understanding of the current peer-reviewed literature will enable the clinician to determine when to conduct a PET study and appreciate its utility in areas such as suspected multivessel disease. This program will focus on the clinical application of cardiac PET through a case-based approach. The case will be illustrated with images, their interpretation, and supportive literature. Educational ObjectivesAudience This program is intended to meet the educational needs of cardiologists, radiologists, technologists, and other health care professionals involved in the diagnosis and management of patients at risk for or with cardiac disease. Agenda 6:30 PM - Registration and Dinner 7:00 PM - Welcome and Introduction 7:05 PM - Slide Presentation 7:45 PM - Question and Answer 8:00 PM - Adjourn Credit Designation Statement Physicians SCEPTER designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Technologists Category A CE credit is pending approval by the American Society of Radiologic Technologists (ASRT). Accreditation Statement SCEPTER is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. Fee Information There is no fee to participate in this educational activity. FACULTY Program Chair Gary V. Heller, MD, PhD Professor of Medicine University of Connecticut School of Medicine Farmington, Connecticut Director, Nuclear Cardiology Laboratory Associate Director, Division of Cardiology Hartford Hospital Hartford, Connecticut Additional Speakers
DISCLOSURE INFORMATION Policy on Disclosure SCEPTER and Quintiles Medical Education adhere to the ACCME Essential Areas and Policies, including the Standards for Commercial Support, regarding industry support of CME. Disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships, as well as the discussion of unlabeled or unapproved use of any drug, device, or procedure by the faculty, will be disclosed to learners. Disclaimer The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor, the educational partner, or the supporter. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients. PRIVACY POLICY To review SCEPTER’s privacy policy, Click Here |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|